MicronJet microneedle device, that have shown improved immunogenicity and reduction of vaccine doses by 5 fold with various vaccines and vaccine platforms.
Novel Coronavirus presents a global pandemic with unprecedented medical, economic and social scales. Since there is currently no proven antiviral therapy and herd immunity is likely months away, the race for finding a vaccine is in full swing on a global level. Considering this urgent need,
The company’s technology is backed up by over 55 completed/ongoing clinical studies with various vaccines and vaccine platforms, including pandemic (H1N1, H5N1) and seasonal flu, live attenuated VZV vaccine, that have shown improved immunogenicity and significant dose-sparing. Pre-clinical evidence with mRNA and DNA vaccines showed promising results.
NanoPass has previously supported US CDC in a Phase 3 infant polio vaccination trial; with ITRC on PPD skin testing; in Type 1 Diabetes immunotherapy; and supported NIAID with devices to evaluate immunogenicity of a pandemic flu vaccine; and multiple vaccine pharma.
For more information, visit nanopass.com
Tell Us What You Think!